Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report
Keyword(s):
The Past
◽
CLL is frequently complicated by autoimmune phenomena (up to 25% of patients) which are sustained by dysfunctions of the immune system. AIHA results the commonest form. In the past decade small molecules had dramatically change the therapeutic scenario of CLL. Their role in the setting of autoimmune phenomena has to be still elucidated. Here we report the case of a CLL patient harboring del (17p) in relapse of disease during ibrutinib therapy who experienced AIHA. Patient, refractory to steroids, achieved benefit from the administration of rituximab and venetoclax. The patient reached stable and long-lasting stabilization of hemoglobin values.
2019 ◽
Vol 12
◽
pp. 1179545X1989457
2015 ◽
Vol 57
(3)
◽
pp. 735-737
◽
2013 ◽
Vol 13
(4)
◽
pp. 511-513
◽
1996 ◽
Vol 38
(4)
◽
pp. 359-360
◽
2018 ◽
Vol 12
(1)
◽
pp. 99-102
◽
2017 ◽
Vol 30
(3)
◽
pp. 343-345
◽
2015 ◽
Vol 56
(4)
◽
pp. 1115-1122
◽